Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 8/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 8/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10566894 | 0.85 | KMT2A (0.47) | POLBKMT2AP2RX3P2RX2SMN1; SMN2 | |
| SCHEMBL12235181 | 0.80 | P2RX3 (0.35) | P2RX3P2RX2 | |
| SCHEMBL10689547 | 0.77 | AOC3 (0.34) | POLBKMT2AP2RX3P2RX2AOC3 | |
| SCHEMBL20116948 | 0.77 | KMT2A (0.39) | POLBKMT2AP2RX3P2RX2AOC3 | |
| SCHEMBL30729970 | 0.75 | NUDT1 (0.49) | KMT2AP2RX3P2RX2MAPT | |
| SCHEMBL27035942 | 0.75 | NUDT1 (0.49) | KMT2AP2RX3P2RX2MAPT | |
| SCHEMBL15431031 | 0.73 | PIK3CA (0.33) | P2RX3P2RX2ALDH1A1GAA | |
| SCHEMBL29333344 | 0.73 | MAPT (0.35) | POLBP2RX3P2RX2GAAMAPT | |
| SCHEMBL22630761 | 0.73 | LRRK2 (0.37) | P2RX3P2RX2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12413949 | 0.73 | GAA (0.37) | P2RX3P2RX2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | POLB 3788/4885KMT2A 2479/4885P2RX3 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.